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Introduction
Maternal mortality remains a major health challenge facing developing countries. Each year more than 280,000 women die due to complications related to childbirth, with the vast majority of these deaths occurring in low-income countries (Lozano et al., 2011) . Very few countries achieved the Millennium Development Goal 5 of reducing maternal mortality by three-quarters by 2015 (Victora et al., 2015) . In low-income countries pre-eclampsia accounts for 11-17% of maternal mortality (Say et al., 2014) . Pre-eclampsia is characterized by high blood pressure and elevated levels of protein in the urine. A diagnosis of pre-eclampsia is made if blood pressure is above 140/ 90 mmHg and there is more than 30 mg/dL of protein in the urine after 20 weeks of gestation (Sibai et al., 2005) . When not properly managed, pre-eclampsia may progress to eclampsia, which is characterized by the onset of seizures and can lead to dangerous complications such as stroke, heart failure, thrombosis, systemic endothelial dysfunction, HELLP syndrome, placental abruption, or even death (Sibai et al., 2005) . The majority of deaths due to pre-eclampsia are preventable if the symptoms can be identified and if treatment can be administered in a timely manner. Treatment for pre-eclampsia consists of medical and surgical options, including the administration of magnesium sulfate and delivery through induction of labor or cesarean section (Altman et al., 2002) .
The diagnosis of pre-eclampsia requires not only skilled health providers, but accurate medical devices that are appropriate for target settings, enabling users to identify pre-eclamptic women when the condition can be managed. In low-and middle-income countries (LMICs) access to the types of medical devices used to diagnose preeclampsia in high-income countries is hindered by high cost, limited trained users and inadequate distribution channels. A recent Lancet Commission called for collective approaches by academia, private sectors, non-governmental and international organizations, and ministries of health to prioritize pressing needs, co-identify appropriate solutions, and devise sustainable implementation plans (Howitt et al., 2012) . Cost-effectiveness analysis provides a unifying framework to guide the allocation of scarce resources to reduce maternal mortality and morbidity. It has important implications for health policy, health care provision, and clinical and biomedical engineering.
Few studies have examined the cost-effectiveness of devices or procedures to reduce maternal mortality in LMICs. Tsu et al. examined the cost-effectiveness of the active management of third-stage labor (Tsu et al., 2009 ). Shmueli et al. performed an economic assessment of screening for pre-eclampsia using uterine artery Doppler and serum biomarkers relative to no screening in an Israeli healthcare system (Shmueli et al., 2012) . Simon et al. assessed the cost-effectiveness of using magnesium sulfate for pre-eclampsia in low-and high-income countries, and the incremental cost of preventing one case of eclampsia (Simon et al., 2006) . Hadker et al. found a novel diagnostic test to be more cost effective in managing a typical pregnancy than blood tests, urine tests, and uterine artery Doppler ultrasounds from the perspective of the UK health system (Hadker et al., 2010) . Meads et al. compared 27 screening tests in a UK setting and found a no-test, treatall strategy to be the most cost effective (Meads et al., 2008) . The current study is the first to generate and compare cost-effectiveness ratios for multiple medical screening devices specifically designed for use in LMICs.
The purpose of this study is three-fold: (1) to tabulate cost and effectiveness data for medical devices appropriate for diagnosing preeclampsia in LMICs, (2) to develop a decision-tree framework for evaluating interventions that improve diagnosis and treatment of preeclampsia based on the costs and benefits to society as a whole, and (3) to generate cost-effectiveness estimates to guide decision-making in clinical practice and health policy to ultimately reduce maternal mortality. This study presents findings from a decision analysis model of medical devices used to diagnose pre-eclampsia in the population of pregnant women residing in LMICs from a societal perspective.
Methods
To identify the set of medical devices to include in this study we conducted several literature searches using PubMed, SciVerse Scopus, WHO Compendia of New and Emerging Health Technologies, Appropedia's Medical Devices Compendium and Medline. We contacted both health care professionals in the field of maternal health and product developers involved in the design and testing of maternal health related medical devices designed for use in LMICs to inquire about prototypes in the pipeline. Of the initial list of 15 devices identified, only eight devices had sufficient cost and effectiveness data to be included in the study (Table 1) .
Pre-eclampsia is diagnosed by blood pressure measurement with subsequent confirmation of proteinuria by urinalysis. The mercury sphygmomanometer is the widely accepted "gold standard" manual blood pressure measurement device. The other blood pressure measurement devices in the study are either automatic or semi-automatic and designed for use in LMICs. Both auscultatory and oscillometric The appropriate sensitivity and specificity measurements for each device were drawn from the literature (Table 1) . We calculated sensitivity values for the blood pressure devices using the biascorrected modeling methodology of Wan et al., which predicts sensitivity rates based on information on the mean and standard deviation using predictions from regression modeling of studies included in the systematic review parameters (Wan et al., 2010) . Costs were obtained from the literature where available, and otherwise directly from the manufacturer or distributor.
We developed a decision-tree framework for a study population of pregnant women in LMICs (Fig. A1 ). The decision tree models the probability that a pregnant woman is tested, stepwise, first for preeclampsia (i.e. blood pressure measurement), followed by confirmatory proteinuria analysis for women with blood pressures above 140/ 90 mmHg, correctly diagnosed, and treated successfully. Each terminal node reveals the disability-adjusted life years (DALYs) associated with a particular sequence of patient outcomes. We used standard costeffectiveness methodology to assess costs, DALYs gained relative to the baseline and incremental cost per DALY gained (Gold et al., 1996; Drummond et al., 2005) . We identified undominated, absolute dominated and extended dominated interventions. The parameter values in the model reflect the generally available standard of access and care based on our review of the literature and expert opinion ( Table 2) . We also performed a comprehensive set of sensitivity analyses to evaluate the robustness of our findings to changes in parameter values.
No official measures are recorded for pre-eclampsia testing rates in LMICs, so we assumed that women are tested for pre-eclampsia if they have attended at least four antenatal care visits (51% of pregnancies). This assumption is conservative; many women will be tested for preeclampsia during one of the first three pre-natal visits, especially if these visits occur late in the pregnancy. Our estimate of the survival rate of untreated pre-eclampsia comes from a population-based survey of a cohort of over 20,000 pregnant women in six West African countries (Prual et al., 2000) . Nevertheless, the sensitivity analysis includes results from the range of parameter values found in the literature (78.8-85.6%) (Prual et al., 2000; Mwinyoglee et al., 1996) . We modeled magnesium sulfate injection as the standard management technique for pre-eclampsia because it has been accepted as the "drug of choice" for treating pre-eclampsia and is included on the WHO's list of priority medicines for mothers and children, the package of commodities needed to achieve the Millennium Development Goal 5 (Sheth and Chalmers, 2002) . Magnesium sulfate is easy to administer, even in LMICs, and demonstrably extremely effective, with a success rate of 99.2% in a large international trial (Altman et al., 2002) . False positives receiving magnesium sulfate should not experience a negative impact on mortality or morbidity. Side effects of the treatment are minimal and rare. The availability of magnesium sulfate is poor in LMICs despite its recent addition to essential drug lists. With little data available about the availability of magnesium sulfate, we used 16% as our best base case estimate based on author's (Johnson) experience, but also examined a wide range of possible values so that our results are generalizable to many settings. If magnesium sulfate is unavailable, clinicians may provide valium or a lytic cocktail, however these alternatives will have little to no effect on mortality rates. Cost of treatment with magnesium sulfate was estimated as $13 and $18 per treatment in low-and middle-income countries, respectively (Simon et al., 2006) . The cost of severe morbidity due to eclampsia is $80 and $722 in low-and middle-income countries, respectively (Simon et al., 2006) . To calculate DALYs associated with the 3.8% of cases resulting in permanent disability due to severe complications of pre-eclampsia, we used a health-related quality of life (HRQL) weight of 0.25 (Lee et al., 2010; Åberg et al., 2011; World Health Organization, 2004) . The only parameters in the model that vary by device are sensitivity and specificity. The time period of analysis capture outcomes for the entire lifespan of the pregnant women in our simulation.
All costs are expressed in 2015 U.S. dollars and, in the absence of available data on training or maintenance costs, reflect only the incremental cost of purchasing the device. The devices are designed to be easy to use and require minimal training; their use can be incorporated into existing provider care and no additional equipment is needed. We therefore do not include provider training, time, or additional equipment costs.
To identify the impact of uncertainty about parameter values on our results we performed one-way sensitivity analyses as well as secondorder probabilistic multivariate sensitivity analyses. We performed a standard set of 5000 independent Monte Carlo simulations where the outcome at each node of the decision tree was determined by draws from independent binomial distributions. For parameters that the oneway sensitivity analyses identified as being particularly influential, we examined a wide range of plausible values in the Monte Carlo analysis. Because survival rates with and without access to pre-eclampsia treatment are correlated, we examined two additional scenarios: a high-resource/high-skill environment with higher than base-case survival rates at all terminal nodes and a low-resource/low-skill environment with relatively lower survival rates at all terminal nodes. Analyses were performed with TreeAge Pro 2015. Table 3 shows the main results on the cost-effectiveness of each intervention. Because the DALYs averted for each device were very similar, the results primarily depended on the per-use cost ranking. With the lowest combined per-use cost of 0.204 cents and incremental cost-effectiveness ratio of $93.6 per DALY gained relative to a baseline scenario with no access to testing or treatment, the Microlife semiautomatic blood pressure monitor with the Uristik single-use proteinuria strips was the most cost-effective combination of medical devices to improve the diagnosis of pre-eclampsia. The device combinations on the cost-effectiveness frontier (undominated) were, in order of increasing incremental cost-effectiveness ratio: Nissei DM3000/CLINITEK strip test, the sphygmomanometer/CLINITEK strip test, and the sphygmomanometer/DCA 2000+. The SpotVital blood pressure device and the Multistix proteinuria test were strongly dominated in all combinations. To be on the cost-effectiveness frontier, the SpotVital device would need to have a per-use cost that implies well over 10,000 uses at the quoted price, which is implausible in LMICs. Extended (weak) dominance ruled out two combinations: Nissei DM3000/Uristik and sphygmomanometer/Uristik. We performed one-way sensitivity analyses of the results to changes in our benchmark model parameters (see tornado diagram in Fig. 1) . Our results were most sensitive to the specificity rate for the blood pressure device. Our results were insensitive to parameter values that were very high (treatment success rate, survival rate for untreated preeclampsia) or very low (rate of pre-eclampsia, rate of severe morbidity due to untreated or unsuccessfully treated pre-eclampsia).
Results
To address the issue that minimal clinical trial data exists to identify some of our benchmark decision tree parameters, we present the results of a comprehensive sensitivity analysis (Table 4 ). The first column shows results from a set of simulations based on the base case parameters for the most cost-effective device combination of the Microlife blood pressure measurement device with the Uristik proteinuria strips. The largest improvements in the incremental cost-effectiveness ratio (ICER) come from increases in the specificity of the blood pressure measurement (Microlife) and the treatment access rate for pre-eclampsia. It is worth noting that in countries with a life expectancy greater than 65 years, this intervention pays for itself. In no case does the ICER estimate for the Microlife, the most cost-effective pre-eclampsia diagnosis device, exceed the threshold to be considered cost-effective in low-income countries (World Health Organization, 2013) .
Survival rates for untreated pre-eclampsia and successfully treated pre-eclampsia are likely to be positively correlated based on overall health status, access to health care, available health resources and the skill level of health care providers. Columns 2 and 3 of Table 4 show the results from a similar sensitivity analysis as Column 1, but using the high-resource and low-resource scenario values. These scenarios typify comparisons of countries (e.g. South Africa vs. Nigeria or India), regions (e.g. urban vs. rural), or facility types (e.g. tertiary hospital Table 3 Costs, DALYs averted and incremental cost effectiveness ratios (ICER) for devices used to detect pre-eclampsia.
Device
Total cost of intervention vs. local clinic). The Microlife device had an ICER of $78.88 in the low resource environment relative to the benchmark scenario with no access to testing and $115.05 in the high resource environment.
Discussion
Our findings show that among the devices analyzed, the most costeffective devices for diagnosing pre-eclampsia are simple rather than complex medical devices. For example, the Microlife blood pressure device is manually inflated but provides automated read-outs, and the Uristik strip test is read visually, in comparison with devices such as the SpotVital Signs or the DCA 2000+ which are fully automated. The most cost-effective devices are all low-cost and feasible to implement even in low-income countries. These devices are likely to be at least as cost-effective as screening for pre-eclampsia using uterine artery Doppler and serum biomarkers (Shmueli et al., 2012) , prophylactic magnesium sulfate for pre-eclampsia (Simon et al., 2006) , communitybased distribution of misoprostol for treatment or prevention of postpartum hemorrhage (Sutherland et al., 2010) , screening for bacteriuria or syphilis, skilled birth attendance, and management of obstructed labor, post-partum hemorrhage and maternal sepsis (Adam et al., 2005) . Furthermore, these devices are well within the range considered cost-effective in low-income countries based on the World Health Organization definition.
Our cost-effectiveness estimates were not particularly sensitive to changes in testing rate, however they were sensitive to changes in device specificity and the treatment access rate (Table 4) . Increasing the testing rate by 20% points (from 40% to 60%) had almost no effect on the ICER whereas increasing the blood pressure device specificity by 20% points (from 70% to 90%) reduced the ICER by $180. Intuitively, there is little benefit to identifying pre-eclamptic women when treatment access is low. This has important implications for device design: when treatment rates are low, a reasonably sensitive device that is low in cost is preferred to a highly-sensitive but high-cost device. When it comes to design for global health, the perfect may be the enemy of good.
Our results highlight the importance of two desirable features for LMIC settings: reusability and accuracy in the absence of calibration. High recurring costs, such as single-use components and maintenance costs, limit the cost-effectiveness of these devices in low-income countries. Even though Microlife and Nissei DM3000 require batteries (or AC power) to operate, their batteries are rechargeable rather than disposable. The most cost-effective devices for blood pressure measurement (Microlife, Nissei DM3000 and Mercury sphygmoman-ometer) are highly accurate and require limited to no calibration.
Other major design features common to the most cost-effective devices are the ability to withstand variable environmental conditions (temperature and humidity), portability and ease of use, which are essential characteristics of devices to be used by health care workers in rural areas. Microlife and Nissei DM3000 have digital screens for displaying blood pressure, which minimizes the likelihood of human error. Uristik and Multistix test strips can be easily interpreted by the immediate change in color in response to the urine droplet.
Our assumptions are all conservative and our results are robust to variance on the dimensions of uncertainty as demonstrated in Table 4 . Our estimates understate the DALYs gained from each device in that they don't include the health benefits to the unborn child from improved diagnosis of pre-eclampsia, which are likely quite substantial. These results do not provide accurate absolute cost effectiveness of testing in scenarios where diagnostic equipment are not already accessible and must be purchased; however, the analysis does provide informative data on the relative cost effectiveness of testing women for preeclampsia using these common technologies.
One limitation of our study is the limited data available on several input parameters of our model and on medical device effectiveness and maternal mortality in general. More precise measures of these input parameters will improve our cost-effectiveness estimates to better guide implementation and health policy. Values from standardized trials similar to the MAGPIE trial that compare effectiveness across devices and across settings would be ideal. We have addressed this limitation with a comprehensive set of probabilistic sensitivity analyses, however, additional effectiveness and survival data would enable us to widen the range of devices examined and draw more specific policy implications from the study. We are not able to model the full cost structure due to limited data on labor costs for training and delivering the test, device maintenance costs, time patients spend traveling and waiting for care, costs of follow-on-care following serious complications due to pre-eclampsia and offsetting health care cost savings due to prevented cases of eclampsia.
Cost-effectiveness analysis considers every stage of implementation in the local environment from when the patient presents at a health facility through diagnosis, treatment and patient outcome. By taking into account the big picture, it makes implicit tradeoffs explicit such as diagnosis versus treatment or cost versus effectiveness. In settings where treatment is rationed or unavailable, the most effective diagnostic device is not necessarily the most desirable, but rather the one that achieves a certain threshold of effectiveness at the lowest cost. Our results provide additional evidence that "hand me down" technology from high-income countries is unlikely to be appropriate in LMICs because developed countries have focused on the most effective solution, regardless of cost (Howitt et al., 2012; Malkin, 2007; Free, 2004) .
Our results have important implications for routine healthcare provision in both clinical and policy contexts. While other studies have evaluated the cost effectiveness of screening and treatment strategies in high income countries, to our knowledge no other study has evaluated the cost effectiveness of medical screening technologies designed for use in LMIC. Cost-effectiveness analysis is an important tool that incorporates information about the local environment to produce tailored policies, devices, and procedures. These are the type of results needed to inform evidence-based medicine, which allows policymakers to standardize procedures in LMICs and thereby reduce maternal mortality. This study was designed to help translate scientific advances into policy and practice in LMICs. We provide a clear framework for decision-making and assess the areas that are most sensitive to uncertainty. In the era of implementation science and implementation engineering, cost-effectiveness should guide not only the development of new devices and procedures but also the implementation and evaluation (Johnson, 2013) . Table 2. 
